Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Genetically prioritized druggable targets for amyloid-β pathology highlight <i>ACE</i> as a therapeutic candidate in Alzheimer's disease.

Journal of Alzheimer's disease : JAD·2026
Same author

Germline APOE ε2 homozygosity and reduced risk of breast cancer: a population-based cohort study.

Breast cancer research : BCR·2026
Same author

Longitudinal plasma p-tau217 as a marker for tracking progression and predicting cognitive decline in Alzheimer's disease.

Alzheimer's research & therapy·2026
Same author

Demographic, Social, and Clinical Profiles of Patients Initiating Lecanemab in Clinical Practice: A Single-Center Experience in Korea.

Dementia and neurocognitive disorders·2026
Same author

Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide association studies.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Deciphering the role of endolysin LysCPD7 harboring C. perfringens spore binding domain.

Microbiological research·2026
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Jihwan Yun1, Daeun Shin2, Eun Hye Lee2

  • 1Kyung Hee University Medical Center, Seoul, Korea, Republic of (South).

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

调整化化 (p-tau) 217切割值用于功能,BMI和贫血,可以改善阿尔茨海默病的检测. 量身定制值可以提高诊断准确度,特别是在功能受损的患者中.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 生物标志物研究 生物标志物研究
  • 阿尔茨海默氏症疾病的诊断方法

背景情况:

  • 化化 (p-tau) 217是检测粉样β (Aβ) 阳性的有前途的生物标志物.
  • 诸如功能障碍,体重指数和贫血等因素可以影响p-tau217水平.
  • 最佳的p-tau217切断需要在不同的生理条件下进行调查.

研究的目的:

  • 为了确定血p-tau217的最佳切割值如何随着估计的膜过率 (eGFR),体重指数 (BMI) 和贫血而变化.
  • 评估这些因素对p-tau217对Aβ阳性的诊断准确性的影响.

主要方法:

  • 一项针对2571名具有不同认知状态的参与者的多中心研究.
  • 血p-tau217测量使用Alzpath Simoa免疫测试与Aβ PET成像一起测量.
  • 参与者根据eGFR,BMI和贫血状况进行分类,以确定调整后的p-tau217截止值.

主要成果:

  • 在患有功能障碍 (例如,eGFR <45),体重不足,肥胖和贫血的个体中观察到较高的最佳p-tau217截止值.
  • 在严重功能障碍组 (eGFR <45) 应用标准切线将诊断准确度降低到48.3%.
  • 调整的切断值提高了诊断性能,突出了个性化值的必要性.

结论:

  • 根据功能,BMI和贫血来定制血p-tau217切断值对于准确的阿尔茨海默病诊断至关重要.
  • p-tau217的诊断效用受到这些生理参数的显著影响.
  • 对于患有功能损害 (eGFR <45) 的患者群体,具体的调整至关重要.